Title:
IL-12 EXPRESSION CONTROLLING AGENTS
Document Type and Number:
WIPO Patent Application WO/2002/074318
Kind Code:
A1
Abstract:
It is intended to provide IL-12 expression controlling agents, expression inhibitors and IL-12 expression potentiators for oral administration containing hyaluronic acid as the active ingredient. Interleukin 12 expression controlling agents containing hyaluronic acid as the active ingredient. More specifically, interleukin 12 expression inhibitors containing hyaluronic acid having a weight-average molecular weight of 600,000 to 3,000,000 or a pharmaceutically acceptable salt thereof as the active ingredient; and interleukin 12 expression potentiators for oral administration containing hyaluronic acid having a weight-average molecular weight of from 50,000 to 400,000 or a pharmaceutically acceptable salt thereof as the active ingredient.
Inventors:
ASARI AKIRA (JP)
KURIHARA HITOSHI (JP)
KURIHARA HITOSHI (JP)
Application Number:
PCT/JP2002/002433
Publication Date:
September 26, 2002
Filing Date:
March 14, 2002
Export Citation:
Assignee:
SEIKAGAKU KOGYO CO LTD (JP)
ASARI AKIRA (JP)
KURIHARA HITOSHI (JP)
ASARI AKIRA (JP)
KURIHARA HITOSHI (JP)
International Classes:
A61K31/728; A61P3/10; A61P13/12; A61P17/00; A61P17/06; A61P19/00; A61P25/00; A61P27/02; A61P29/00; A61P37/04; A61P37/08; A61P43/00; (IPC1-7): A61K31/728; A61P43/00; A61P17/00; A61P27/02; A61P37/08; A61P37/04; A61P3/10; A61P25/00; A61P29/00; A61P19/00; A61P17/06; A61P13/12; C08B37/08
Other References:
HODGE-DUFOUR JENNIFER ET AL.: "Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages", J. IMMUNOL., vol. 159, no. 5, 1997, pages 2492 - 2500, XP002951519
Attorney, Agent or Firm:
Oguri, Shohei (ARK Mori Building 12-32 Akasaka 1-chome Minato-ku, Tokyo, JP)
Download PDF: